Overview
- Pee Safe closed a $32 million Series C led by healthcare investor OrbiMed, structured as a mix of primary capital and secondary share sales that enabled partial exits for early backers.
- OrbiMed’s Dr Sunny Sharma and Sumona Chakraborty will join the company’s board, formalizing the investor’s operational involvement.
- The company said it will deploy the funds to deepen retail distribution, step up brand-led marketing, and scale across quick‑commerce platforms and major marketplaces, with an emphasis on wider reach beyond top metros.
- Pee Safe reports an annualised net revenue run rate of over Rs 150 crore and says it remains profitable.
- The brand has moved beyond toilet-seat sanitisers into feminine and intimate hygiene, personal care, grooming and wellness, and claims presence in 50,000+ offline touchpoints across 100+ cities with exports to 23 markets.